|

Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients

RECRUITINGSponsored by Sohag University
Actively Recruiting
SponsorSohag University
Started2026-09-01
Est. completion2027-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), with the goal of improving early risk stratification and clinical decision-making.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years old.
* Both sexes.
* Diagnosis of ST-segment elevation myocardial infarction (STEMI) according to current ESC/ACC guidelines.
* Presentation within 12 hours of symptom onset.
* Undergoing primary percutaneous coronary intervention (PCI) as the reperfusion strategy.

Exclusion Criteria:

* Active infection or sepsis.
* Chronic inflammatory or autoimmune diseases.
* Hematological disorders.
* Active malignancy.
* Severe liver disease.
* End-stage renal disease requires dialysis.
* Previous coronary artery bypass graft surgery (CABG).
* Current use of chronic corticosteroid or immunosuppressive therapy.

Conditions7

Coronary No-ReflowHeart DiseaseImmune-InflammatoryIntegrated AssessmentMetabolic BiomarkersPrimary Percutaneous Coronary InterventionST Segment Elevation Myocardial Infarction

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.